A Phase 2 interventional study of Lenalidomide in Leukemia, Myeloid, sponsored by Celgene. Completed at 62 sites in 2 countries. Open to participants aged 1 Year to 18 Years. Per ClinicalTrials.gov, last updated 2020-01-07.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies testing lenalidomide in Leukemia, Myeloid, Acute — none open to participants now, none under way, none of them phase 3. Lenalidomide · Leukemia, Myeloid, Acute.
Among the 33 studies testing lenalidomide in Leukemia, Myeloid, Acute, this one is the 24th largest by enrollment of the 32 interventional ones that give a count, is one of 4 that started in 2015, is one of 14 in phase 2, and was the 32nd registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 816 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →None of the 33 studies testing lenalidomide in Leukemia, Myeloid, Acute is open now. The open studies under Leukemia, Myeloid, Acute, anywhere →
Lenalidomide: first FDA approval 2005 (REVLIMID), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 1 Year to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 19 · Phase 3 1
First in 2006; this study’s year is marked. 4 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 17 is below the median of 40 across 3,006 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 33 across the 32 interventional studies. Of the 30 that completed or were terminated, 14 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 33 have an industry lead sponsor. The 10 most frequent:
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
43 studies in Leukemia, Myeloid, Acute by Bristol-Myers Squibb: 1 open now, 4 under way, none of them phase 3. Of 36 finished, 9 (25%) have results posted.
Among the 43 studies in Leukemia, Myeloid, Acute by Bristol-Myers Squibb, this one is the 25th largest by enrollment of the 30 interventional ones that give a count, is one of 2 that started in 2015, is one of 8 in phase 2, and was the 19th registered.
Bristol-Myers Squibb’s Leukemia, Myeloid, Acute studies by the year they started, since 2006.
None of the studies under way reaches primary completion within a year.
Among the 33 studies testing lenalidomide in Leukemia, Myeloid, Acute, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bristol-Myers Squibb’s 43 in Leukemia, Myeloid, Acute:
This tab as a report to print or save as PDF → With an account.
To determine the activity of lenalidomide in the treatment of pediatric subjects with relapsed/refractory acute myeloid leukemia (AML) (with second or greater relapse or refractory to at least 2 prior induction attempts) measured by morphological complete response defined as either a CR or CRi within the first 4 cycles of treatment.
This is a multicenter, open-label, single-arm, Phase 2, Simon's Optimal two-stage design study, with an Optional Extension Phase (OEP), that will assess the activity, safety and pharmacokinetics (PK) of lenalidomide in pediatric subjects from 1 to ≤ 18 years of age with second or greater Relapsed or Refractory Acute Myeloid Leukemia (rrAML). A total of 43 evaluable participants (18 participants in Stage 1 and an additional 25 participants in Stage 2) are required for assessment of the primary endpoint. To allow for participants found to be unevaluable for the primary endpoint due to an incorrect diagnosis, not having a disease assessment post screening, or who discontinued prior to receiving lenalidomide, up to 4 additional participants may be enrolled for a maximum of 47 evaluable subjects across approximately 70 sites. Approximately 50% of enrolled participants will be younger than 12 years of age to provide adequate PK data for this age subset.
If during Stage 1, at least 3 of 18 participants achieve a morphologic complete response (either CR or CRi) within the first 4 cycles of study treatment, then the study will proceed to Stage 2; otherwise, the study will be terminated. Similarly, if at the final analysis, at least 8 of 43 evaluable subjects across Stages 1 and 2 achieve a response (CR/CRi) within the first 4 cycles of study treatment, it will be concluded that lenalidomide has sufficient activity in pediatric Acute Myeloid Leukemia (AML) to warrant subsequent study. The optional extension phase (OEP) will allow participants who demonstrate clinical benefit, as assessed by the Investigator at the completion of 12 cycles of lenalidomide therapy, to continue receiving oral lenalidomide until they meet the criteria for study discontinuation. In the OEP, only safety, dosing, concomitant medications/procedures, and second primary malignancies (SPMs) will be monitored.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 816 are open to participants now.
This study's enrollment of 17 is below the median of 40 across 3,006 interventional studies indexed under Leukemia, Myeloid, Acute.
Browse Leukemia, Myeloid, Acute studies →Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
First submitted before Celgene became part of Bristol-Myers Squibb.
Compared within Leukemia, Myeloid, Acute, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Leukemia, Myeloid. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants have acute myeloid leukemia after at least 2 prior induction attempts:
Regarding radiation therapy, time elapsed prior to first dose of lenalidomide:
criteria:
If the participants have a history of maximum Grade 1 or 2 GVHD that was treated with systemic (≥ 0.5 mg/kg/day prednisone equivalents) or other non-steroid systemic IST, the participant must be off all IST for at least 2 weeks, and must have ceased treatment doses of steroids for GVHD (≥ 0.5 mg/kg/day prednisone equivalents) for at least 4 weeks.
Participants have adequate renal function, which is defined as:
Participants have adequate liver function, which is defined as:
All participants and/or parents/guardians must have an understanding that lenalidomide could have a potential teratogenic risk. Female children of childbearing potential, is defined as females who have achieved menarche and/or breast development in Tanner Stage 2 or greater and have not undergone a hysterectomy or bilateral oophorectomy and FCBP defined as a sexually mature woman who has not undergone a hysterectomy or bilateral oophorectomy and has not been naturally for at least 24 consecutive months (ie, has had menses at any time in the preceding 24 consecutive months) must meet the following conditions below (Note: Amenorrhea following cancer therapy does not rule out childbearing potential):
NOTE: The pregnancy test 10 to 14 days prior to initiation of lenalidomide may be omitted, at the discretion of the investigator, for any FCCBP/FCBP who has high acuity disease requiring immediate treatment with lenalidomide. The pregnancy test within 24 hours prior to the first dose of lenalidomide is required to be performed.
The participants may not received Product (IP) until the investigator has verified that the results of these pregnancy tests performed on Cycle 1 Day 1 are negative. FCCBP/FCBP with regular or no menstrual cycles must agree to have pregnancy tests weekly for the first 28 days of study participation and then every 28 days while on study, at study Treatment Discontinuation Visit, and at Day 28 following IP discontinuation. If menstrual cycles are irregular, the pregnancy testing must occur weekly for the first 28 days and then every 14 days while on study, at study Treatment Discontinuation Visit, and at Days 14 and 28 following IP discontinuation.
All male and female participants must follow all requirements defined in the Pregnancy Prevention Program.
Exclusion Criteria:
The presence of any of the following will exclude a participant from enrollment:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lenalidomide API will administered at a starting dose of 2 mg/kg/day. Lenalidomide will be provided as either a capsule (2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg or 25 mg) or as an oral suspension (10mg/mL).
Drug: Lenalidomide
Lenalidomide will be administered orally once daily for the first 21 days of every 28-day cycle. The starting dose will be 2 mg/kg/day with a maximum dose of 70 mg/day. Number of cycles: 12, or until evidence of progressive disease. Participants will also be discontinued if unresolved toxicities as described in the protocol occur, or if dose reductions are required and subject does not tolerate minimum dose level of 1mg/kg/day.
Number of Participants Who Achieved a Morphologic Complete Response Within the First Four Cycles of Lenalidomide Treatment According to the Modified International Working Group (IWG) Criteria
The morphological complete response rate was defined as the total number of participants with morphological CR observed within the first 4 cycles of lenalidomide (regardless of whether the CR/CRi was observed at the end of Cycle 1, 2, 3 or 4) over the total number of participants evaluable for this endpoint. According to Modified IWG criteria, morphologic CR was defined as: 1. Absolute neutrophil count (ANC) ≥ 1000/μL and platelets ≥ 100,000 without transfusions and/or exogenous growth factor support (i.e., no transfusion or exogenous growth factor within 7 days of assessment; 2. Bone marrow \< 5% blasts evidence of trilineage hematopoiesis; 3. No evidence of extramedullary disease. Morphologic CRi was defined as: 1. ANC \< 1000/μL and platelets \< 100,000/μL or \> 100,000/μL without platelet recovery (requiring transfusion within 7 days of assessment); 2. BM with \< 5% blasts and evidence of trilineage hematopoiesis; 3. No evidence of extramedullary disease.
Time frame: From day of the first dose of IP to end of cycle 4; Response was assessed at the completion of the 21-day treatment period of cycles 1, 2, 3, and 4 and at treatment discontinuation.
Number of Participants Who Achieved a Bone Marrow Confirmed CR/CRi Lasting 3 Months (Durable Response Rate)
Durable response rate was defined as the percentage of participants who achieved a BM confirmed CR/CRi according to the Modified IWG Response Assessment Lasting 3 Months (from the time to complete response observed until treatment failure or worse) or until transplantation if earlier among all participants eligible for durable response rate analysis, provided the CR/CRi was confirmed in a bone marrow sample). Due to scarcity of relevant data, it was not practical or meaningful to analyze the durable response rate. Only 1 participant had a response and the participant was censored soon after, as the consent was withdrawn; unable to calculate duration of response.
Time frame: From date of confirmed complete response observed until treatment failure or worse; up to data cut-off date of 31 December 2017
Duration of Response
Duration of response was defined as the time from date of the first observed response (CR, CRi or PR) until morphologic relapse, molecular/cytogenetic relapse, or death only for participants who achieved a response. Due to scarcity of relevant data, it was not practical or meaningful to analyze the duration of response. Only 1 participant had a response and the participant was censored soon after, as the consent was withdrawn; unable to calculate duration of response.
Time frame: From date of first time of complete response observed until treatment failure or worse; up to data cut-off date of 31 December 2017
Number of Participants Who Achieved a Best Response of Morphologic Complete Remission, Morphologic Complete Remission Incomplete or Partial Remission
Overall response rate was defined as the number of participants with best response of CR, CRi or PR. A CR was defined as: 1. ANC ≥ 1000/μL and platelets ≥ 100,000 without transfusions and/or exogenous growth factor support (no transfusion or exogenous growth factor within 7 days of assessment); 2. BM \< 5% blasts evidence of trilineage hematopoiesis; 3. No evidence of extramedullary disease. A CRi was defined as: 1. ANC \< 1000/μL and platelets \< 100,000/μL or \> 100,000/μL without platelet recovery (requiring transfusion within 7 days of assessment); 2. BM with \< 5% blasts and evidence of trilineage hematopoiesis; 3. No evidence of extramedullary disease. A PR was defined as: 1. ANC of ≥ 1000/μL and platelets ≥ 100,000 without transfusions and/or exogenous growth factor support (no transfusion or exogenous growth factor within 7 days of assessment); 2. BM with 5% to 25% blasts and at least a 50% decrease in BM blast percent from baseline; 3. No evidence of extramedullary disease.
Time frame: Response was assessed at the completion of the 21-day treatment period of cycles 1, 2, 3.
Number of Participants With a Morphologic CR, CRi, PR or Treatment Failure at Cycles 1, 2 and 3
Disease assessment outcome at the end of Cycles 1-3 based on Cheson criteria: Morphologic CR = 1. ANC ≥ 1000/μL and platelet ≥ 100,000 without transfusions and/or exogenous growth factor support (no transfusion or exogenous growth factor within 7 days of assessment) 2. BM \< 5% blasts evidence of trilineage hematopoiesis 3. No evidence of extramedullary disease Morphologic CRi = 1. ANC\< 1000/μL and Platelets \< 100,000/μL or \> 100,000/μL without platelet recovery (requiring transfusion within 7 days of assessment) 2. BM with \< 5% blasts and evidence of trilineage hematopoiesis 3. No evidence of extramedullary disease PR = 1. ANC ≥ 1000/μL and platelets ≥ 100,000 without transfusions and/or exogenous growth factor support 2. BM with \< 5%-25% blasts and at least a 50% decrease in BM blast percent from baseline 3. No evidence of extramedullary disease Treatment Failure = resistant disease; survival ≥ 7 days post-therapy; failed to achieve CR, CRi, or PR but stable with persistent AML
Time frame: Response was assessed at the completion of the 21-day treatment period of cycles 1, 2, 3.
Number of Participants Who Received a Haematopoietic Stem Cell Transplant (HSCT)
The number of participants who had undergone a haematopoietic stem cell transplant was calculated over the total number of participants in the ITT population. Percentages were also calculated based on whether the transplantation was the first, second, or subsequent transplant post IP administration.
Time frame: From first dose of study drug up to 5 years post HSCT
Number of Participants Who Experienced Treatment Emergent Adverse Events (TEAE)
A TEAE was defined as any adverse event (AE) occurring or worsening on or after the first treatment of lenalidomide and within 28 days after the last dose. A serious AE = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs was graded based on National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 4.3 and based on the following scale: Grade 1 = Mild Grade 2 = Moderate Grade 3 = Severe Grade 4 = Life threatening Grade 5 = Death.
Time frame: From the first dose of study drug until 28 days after the last dose of study drug; up to data cut off date of 31 December 2017; maximum duration of treatment was 12 weeks
Percentage of Participants With of Graft Versus Host Disease (GVHD)
Acute graft versus host disease generally occurs after allogeneic hematopoietic stem cell transplantation. It is a reaction of donor immune cells against host tissues. The 3 main tissues that acute GVHD affects are the skin, liver, and gastrointestinal tract. Chronic GVHD is scored per the National Institute of Health consensus conference grading system. Clinical manifestations of chronic GVHD include skin involvement resembling lichen planus or the cutaneous manifestations of scleroderma; dry oral mucosa with ulcerations and sclerosis of the gastrointestinal tract; and a rising serum bilirubin concentration.
Time frame: From the first dose of study drug to 28 days after the last dose of study drug; up to data cut off date of 31 December 2017; maximum treatment was 12 weeks
Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration of Lenalidomide (AUC-t)
Area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration, calculated by linear trapezoidal method when concentrations were increasing and the logarithmic trapezoidal method when concentrations were decreasing.
Time frame: Pharmacokinetic (PK) sampling was conducted after lenalidomide administration at Cycle 1 and was weight dependent at these timepoints: 0.5, 1, 2, 4, 6, 8 and 24 hours. The 24 hour PK sample was taken prior to the lenalidomide dose on Day 2.
Area Under the Plasma Concentration Time Curve From 0 Extrapolated to Infinity (AUC-inf, AUC0∞) Of Lenalidomide
Area under the plasma concentration-time curve from time 0 extrapolated to infinity, calculated as \[AUCt + Ct/ λz\]. Ct is the last quantifiable concentration. No AUC extrapolation was performed with unreliable λz.
Time frame: Pharmacokinetic sampling was conducted after lenalidomide administration at Cycle 1 and was weight dependent at these timepoints: 0.5, 1, 2, 4, 6, 8 and 24 hours. The 24 hour PK sample was taken prior to the lenalidomide dose on Day 2.
Maximum Observed Concentration (Cmax) of Lenalidomide
Maximum observed plasma concentration, obtained directly from the observed concentration versus time data.
Time frame: PK sampling was conducted after lenalidomide administration at Cycle 1 and was weight dependent at these timepoints: 0.5, 1, 2, 4, 6, 8 and 24 hours. The 24 hour PK sample was taken prior to the lenalidomide dose on Day 2.
Time to Reach Maximum Concentration (Tmax) of Lenalidomide
Time to cmax was obtained directly from the observed concentration versus time data.
Time frame: Pk sampling was conducted after lenalidomide administration at Cycle 1 and was weight dependent at these timepoints: 0.5, 1, 2, 4, 6, 8 and 24 hours. The 24 hour PK sample was taken prior to the lenalidomide dose on Day 2.
Terminal Half-Life (t1/2) of Lenalidomide
Terminal phase half-life in plasma, calculated as \[(ln 2)/λz\]. Terminal half-life was only calculated when a reliable estimate for λz could be obtained.
Time frame: Pharmacokinetic sampling was conducted after lenalidomide administration at Cycle 1 and was weight dependent at these timepoints: 0.5, 1, 2, 4, 6, 8 and 24 hours. The 24 hour PK sample was taken prior to the lenalidomide dose on Day 2.
Apparent Total Clearance (CL/F) of Lenalidomide
Apparent volume of distribution, calculated as \[(CL/F)/λz\].
Time frame: Pharmacokinetic sampling was conducted after lenalidomide administration at Cycle 1 and was weight dependent at these timepoints: 0.5, 1, 2, 4, 6, 8 and 24 hours. The 24 hour PK sample was taken prior to the lenalidomide dose on Day 2.
Apparent Volume of Distribution (Vz/F) of Lenalidomide
Apparent volume of distribution, calculated as \[(CL/F)/λz\].
Time frame: Pharmacokinetic sampling was conducted after lenalidomide administration at Cycle 1 and was weight dependent at these timepoints: 0.5, 1, 2, 4, 6, 8 and 24 hours. The 24 hour PK sample was taken prior to the lenalidomide dose on Day 2.
Correlation of Peripheral White Blood Cell Count, Absolute Blast Count and Cytogenetics With Response to Lenalidomide
Correlation of peripheral white blood cell count, absolute blast count and cytogenetics with response to lenalidomide was not performed since only 1 participant met the primary efficacy endpoint of morphological CR/CRi, and due to scarcity of relevant data, it was not practical or meaningful to analyze to perform the analysis on blood counts and response to lenalidomide.
Time frame: Not Performed
Participants were enrolled at 15 centers within the United States and Canada.
| Milestone | Lenalidomide |
|---|---|
| Started | 17 |
| Completed | 0 |
| Not completed | 17 |
| Withdrew: Other = death due to disease progression | 1 |
| Withdrew: Adverse event | 2 |
| Withdrew: Withdrawal by parent/guardian | 2 |
| Withdrew: Treatment failure | 9 |
| Withdrew: Disease progression | 1 |
| Withdrew: Physician decision | 2 |
| Milestone | Lenalidomide |
|---|---|
| Started | 17 |
| Completed | 0 |
| Not completed | 17 |
| Withdrew: Other = death due to disease progression | 13 |
| Withdrew: Withdrawal by parent | 4 |
The morphological complete response rate was defined as the total number of participants with morphological CR observed within the first 4 cycles of lenalidomide (regardless of whether the CR/CRi was observed at the end of Cycle 1, 2, 3 or 4) over the total number of participants evaluable for this endpoint. According to Modified IWG criteria, morphologic CR was defined as: 1. Absolute neutrophil count (ANC) ≥ 1000/μL and platelets ≥ 100,000 without transfusions and/or exogenous growth factor support (i.e., no transfusion or exogenous growth factor within 7 days of assessment; 2. Bone marrow \< 5% blasts evidence of trilineage hematopoiesis; 3. No evidence of extramedullary disease. Morphologic CRi was defined as: 1. ANC \< 1000/μL and platelets \< 100,000/μL or \> 100,000/μL without platelet recovery (requiring transfusion within 7 days of assessment); 2. BM with \< 5% blasts and evidence of trilineage hematopoiesis; 3. No evidence of extramedullary disease.
| Participants | Lenalidomide |
|---|---|
| Number of Participants Who Achieved a Morphologic Complete Response Within the First Four Cycles of Lenalidomide Treatment According to the Modified International Working Group (IWG) Criteria | 1 (0.1 to 28.7) |
Durable response rate was defined as the percentage of participants who achieved a BM confirmed CR/CRi according to the Modified IWG Response Assessment Lasting 3 Months (from the time to complete response observed until treatment failure or worse) or until transplantation if earlier among all participants eligible for durable response rate analysis, provided the CR/CRi was confirmed in a bone marrow sample). Due to scarcity of relevant data, it was not practical or meaningful to analyze the durable response rate. Only 1 participant had a response and the participant was censored soon after, as the consent was withdrawn; unable to calculate duration of response.
No measurements were reported for this outcome.
Duration of response was defined as the time from date of the first observed response (CR, CRi or PR) until morphologic relapse, molecular/cytogenetic relapse, or death only for participants who achieved a response. Due to scarcity of relevant data, it was not practical or meaningful to analyze the duration of response. Only 1 participant had a response and the participant was censored soon after, as the consent was withdrawn; unable to calculate duration of response.
No measurements were reported for this outcome.
Overall response rate was defined as the number of participants with best response of CR, CRi or PR. A CR was defined as: 1. ANC ≥ 1000/μL and platelets ≥ 100,000 without transfusions and/or exogenous growth factor support (no transfusion or exogenous growth factor within 7 days of assessment); 2. BM \< 5% blasts evidence of trilineage hematopoiesis; 3. No evidence of extramedullary disease. A CRi was defined as: 1. ANC \< 1000/μL and platelets \< 100,000/μL or \> 100,000/μL without platelet recovery (requiring transfusion within 7 days of assessment); 2. BM with \< 5% blasts and evidence of trilineage hematopoiesis; 3. No evidence of extramedullary disease. A PR was defined as: 1. ANC of ≥ 1000/μL and platelets ≥ 100,000 without transfusions and/or exogenous growth factor support (no transfusion or exogenous growth factor within 7 days of assessment); 2. BM with 5% to 25% blasts and at least a 50% decrease in BM blast percent from baseline; 3. No evidence of extramedullary disease.
| Participants | Lenalidomide |
|---|---|
| Number of Participants Who Achieved a Best Response of Morphologic Complete Remission, Morphologic Complete Remission Incomplete or Partial Remission | 1 |
Disease assessment outcome at the end of Cycles 1-3 based on Cheson criteria: Morphologic CR = 1. ANC ≥ 1000/μL and platelet ≥ 100,000 without transfusions and/or exogenous growth factor support (no transfusion or exogenous growth factor within 7 days of assessment) 2. BM \< 5% blasts evidence of trilineage hematopoiesis 3. No evidence of extramedullary disease Morphologic CRi = 1. ANC\< 1000/μL and Platelets \< 100,000/μL or \> 100,000/μL without platelet recovery (requiring transfusion within 7 days of assessment) 2. BM with \< 5% blasts and evidence of trilineage hematopoiesis 3. No evidence of extramedullary disease PR = 1. ANC ≥ 1000/μL and platelets ≥ 100,000 without transfusions and/or exogenous growth factor support 2. BM with \< 5%-25% blasts and at least a 50% decrease in BM blast percent from baseline 3. No evidence of extramedullary disease Treatment Failure = resistant disease; survival ≥ 7 days post-therapy; failed to achieve CR, CRi, or PR but stable with persistent AML
| Participants | Lenalidomide |
|---|---|
| Cycle 1 Morphologic CR | 0 |
| Cycle 1 Morphologic CRi | 0 |
| Cycle 1 PR | 1 |
| Cycle 1 Treatment Failure | 13 |
| Cycle 2 Morphologic CR | 0 |
| Cycle 2 Morphologic CRi | 1 |
| Cycle 2 PR | 0 |
| Cycle 2 Treatment Failure | 5 |
| Cycle 3 Morphologic CR | 0 |
| Cycle 3 Morphologic CRi | 1 |
| Cycle 3 PR | 0 |
| Cycle 3 Treatment Failure | 0 |
The number of participants who had undergone a haematopoietic stem cell transplant was calculated over the total number of participants in the ITT population. Percentages were also calculated based on whether the transplantation was the first, second, or subsequent transplant post IP administration.
| Participants | Lenalidomide |
|---|---|
| Any Transplant After Treatment Start | 2 |
| First Transplant After Treatment Start | 2 |
| Second Transplant After Treatment Start | 0 |
| Any Subsequent Transplant After Treatment Start | 0 |
A TEAE was defined as any adverse event (AE) occurring or worsening on or after the first treatment of lenalidomide and within 28 days after the last dose. A serious AE = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs was graded based on National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 4.3 and based on the following scale: Grade 1 = Mild Grade 2 = Moderate Grade 3 = Severe Grade 4 = Life threatening Grade 5 = Death.
| Participants | Lenalidomide |
|---|---|
| Any TEAE | 17 |
| Any TEAE Related to Lenalidomide | 15 |
| Any Grade 3/4 TEAE | 17 |
| Any Grade 3/4 TEAE Related to Lenalidomide | 11 |
| Any Grade 5 TEAE | 1 |
| Any Serious TEAE | 13 |
| Any Serious TEAE Related to Lenalidomide | 5 |
| Any Serious TEAE Leading to Dose Discontinuation | 3 |
| Any TEAE Leading to Dose Discontinuation | 3 |
| Any TEAE Leading to Dose Reduction | 4 |
| Any TEAE Leading to Dose Interruption | 7 |
| Any TEAE Leading to Death | 1 |
Acute graft versus host disease generally occurs after allogeneic hematopoietic stem cell transplantation. It is a reaction of donor immune cells against host tissues. The 3 main tissues that acute GVHD affects are the skin, liver, and gastrointestinal tract. Chronic GVHD is scored per the National Institute of Health consensus conference grading system. Clinical manifestations of chronic GVHD include skin involvement resembling lichen planus or the cutaneous manifestations of scleroderma; dry oral mucosa with ulcerations and sclerosis of the gastrointestinal tract; and a rising serum bilirubin concentration.
| Percentage of Participants | Lenalidomide |
|---|---|
| Percentage of Participants With of Graft Versus Host Disease (GVHD) | 0 |
Area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration, calculated by linear trapezoidal method when concentrations were increasing and the logarithmic trapezoidal method when concentrations were decreasing.
| ng*h/mL | Lenalidomide |
|---|---|
| Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration of Lenalidomide (AUC-t) | 5378.83 ± 57.3 |
Area under the plasma concentration-time curve from time 0 extrapolated to infinity, calculated as \[AUCt + Ct/ λz\]. Ct is the last quantifiable concentration. No AUC extrapolation was performed with unreliable λz.
| ng*h/mL | Lenalidomide |
|---|---|
| Area Under the Plasma Concentration Time Curve From 0 Extrapolated to Infinity (AUC-inf, AUC0∞) Of Lenalidomide | 5656.67 ± 52.8 |
Maximum observed plasma concentration, obtained directly from the observed concentration versus time data.
| ng/mL | Lenalidomide |
|---|---|
| Maximum Observed Concentration (Cmax) of Lenalidomide | 1252.08 ± 43.8 |
Time to cmax was obtained directly from the observed concentration versus time data.
| Hours | Lenalidomide |
|---|---|
| Time to Reach Maximum Concentration (Tmax) of Lenalidomide | 2.000 (0.5500 to 4.000) |
Terminal phase half-life in plasma, calculated as \[(ln 2)/λz\]. Terminal half-life was only calculated when a reliable estimate for λz could be obtained.
| hours | Lenalidomide |
|---|---|
| Terminal Half-Life (t1/2) of Lenalidomide | 2.311 ± 43.3 |
Apparent volume of distribution, calculated as \[(CL/F)/λz\].
| ml/min | Lenalidomide |
|---|---|
| Apparent Total Clearance (CL/F) of Lenalidomide | 172.09 ± 52.5 |
Apparent volume of distribution, calculated as \[(CL/F)/λz\].
| Liters | Lenalidomide |
|---|---|
| Apparent Volume of Distribution (Vz/F) of Lenalidomide | 34.42 ± 57.0 |
Correlation of peripheral white blood cell count, absolute blast count and cytogenetics with response to lenalidomide was not performed since only 1 participant met the primary efficacy endpoint of morphological CR/CRi, and due to scarcity of relevant data, it was not practical or meaningful to analyze to perform the analysis on blood counts and response to lenalidomide.
No measurements were reported for this outcome.
Collected over From the date of the first dose of lenalidomide until 28 days after the last dose of lenalidomide; up to the date the last patient discontinued follow-up 11 January 2019; maximum treatment duration was 12 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lenalidomide | 13/17 (76.5%) | 13/17 (76.5%) | 17/17 (100%) |
| Event | Lenalidomide |
|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 6/17 |
| CellulitisInfections and infestations | 2/17 |
| PneumoniaInfections and infestations | 2/17 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 2/17 |
| Haemolytic anaemiaBlood and lymphatic system disorders | 1/17 |
| LeukocytosisBlood and lymphatic system disorders | 1/17 |
| Vitreous haemorrhageEye disorders | 1/17 |
| DiarrhoeaGastrointestinal disorders | 1/17 |
| StomatitisGastrointestinal disorders | 1/17 |
| VomitingGastrointestinal disorders | 1/17 |
| Event | Lenalidomide |
|---|---|
| AnaemiaBlood and lymphatic system disorders | 10/17 |
| ThrombocytopeniaBlood and lymphatic system disorders | 10/17 |
| NauseaGastrointestinal disorders | 9/17 |
| HypokalaemiaMetabolism and nutrition disorders | 9/17 |
| ConstipationGastrointestinal disorders | 7/17 |
| PyrexiaGeneral disorders | 7/17 |
| Abdominal painGastrointestinal disorders | 6/17 |
| HeadacheNervous system disorders | 6/17 |
| Back painMusculoskeletal and connective tissue disorders | 5/17 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 5/17 |
The intention to treat (ITT) population consisted of all enrolled participants regardless of whether they received lenalidomide.
| Age, Continuous(years) | Lenalidomide |
|---|---|
| Mean | 11.5 ± 4.56 |
| Sex: Female, Male(Participants) | Lenalidomide |
|---|---|
| Female | 7 |
| Male | 10 |
| Race/Ethnicity, Customized(Participants) | Lenalidomide |
|---|---|
| Asian | 1 |
| Black or African American | 0 |
| White | 12 |
| Not Collected or Reported | 3 |
| Other | 1 |
| Age Categories(Participants) | Lenalidomide |
|---|---|
| ≤ 2 years | 0 |
| 3-6 years | 4 |
| 7-12 years | 6 |
| 13-16 years | 4 |
| ≥ 17 years | 3 |
| Peripheral Blood Smear Blasts(Percent of Blasts) | Lenalidomide |
|---|---|
| Median | 8.7 (0 to 91) |
| White Blood Cell Count(10^9/L) | Lenalidomide |
|---|---|
| Median | 3.700 (0.13 to 158.90) |
| Bone Marrow (BM) Myeloblasts Count(Percent of Myeloblasts) | Lenalidomide |
|---|---|
| Median | 57.5 (7 to 92) |
| Number of Participants With at Least One Cytogenetic Abnormality(Participants) | Lenalidomide |
|---|---|
| t(8;21) | 1 |
| +8 | 1 |
| complex (>/= 3 abnormalities) | 5 |
| -7 | 1 |
| 7q- | 2 |
| 11q 23 abnormalities | 3 |
| inv (3) | 1 |
| Other | 9 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2015 to primary completion in Jul 2017, 20 months.
Results were first posted in Sep 2018, 1 year 1 month after primary completion.
Of 57 industry-sponsored phase 2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 55. This study's 20 months is below that.
Counting every sponsor, half of 443 studies reached it within 60 months; a quarter within 38 and three quarters within 104.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lenalidomide